AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05468060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA1010
Description: Placebo as control
Study NCT01673555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00951379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone hydrochloride
Description: Three (3) pioglitazone 15 mg capsules by mouth once daily for 24 weeks (+/- 1 week)
Study NCT00951379 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Three (3) pioglitazone placebo capsules by mouth once daily for 24 weeks (+/- 1 week)
Study NCT00951379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00951379 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00976937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
Study NCT00976937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lixisenatide Placebo
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
Study NCT00976937 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector
Study NCT00976937 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pen auto-injector
Study NCT00976937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Administered orally once a day in the morning with or without food at approximately the same time each day.
Study NCT00976937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin Placebo
Description: Administered orally once a day in the morning with or without food at approximately the same time each day.
Study NCT00976937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
Study NCT00976937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
Study NCT03359889 — intervention group
Intervention type: DRUG
Intervention: PraxbindTM
Description: Drug
Study NCT01281163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO
Study NCT01281163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01281163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib Ditosylate
Description: Given PO
Study NCT01281163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies
Study NCT01281163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01199575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Study NCT01199575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT02418533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: menotropin
Description: Menopur is used for controlled ovarian stimulation (COH)
Study NCT00513526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: week 0, 8, 24, 128
Study NCT01892553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Procedure : 3 different sessions of tDCS (listed below) presented in random order, each applied at a different study visit~* Anodal tDCS: Intensity of 1.25 milliAmperes (mA) during 15 min~* Cathodal tDCS: Intensity of 1.25 mA during 15 min~* Sham tDCS (placebo) (1.25 mA maintained only during the first 30 sec of the 15 minutes application)
Study NCT02725086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucostim®
Study NCT02418533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recominant Follicle Stimulating Hormone (rFSH)
Description: Gonal-f is used for controlled ovarian stimulation (COH)
Study NCT03299738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-CAR011
Description: Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
Study NCT04385147 — intervention group
Intervention type: OTHER
Intervention: Endoscopic management according to standard of care
Description: Endoscopic management according to standard of care by ERCP or EUS according to the indication in each case
Study NCT01053117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized approach to convert dialysis catheter to fistula
Description: This group will be assigned an algorithm protocol in efforts to convert the central venous catheter to an arteriovenous fistula. A case manager will be assigned to follow these patients and implement the protocol
Study NCT01547468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Catheterization
Description: A femoral nerve catheter will be placed prior to surgery in this group.
Study NCT01547468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Opioids
Description: Intravenous opioids will be given after surgery to provide pain relief to subjects assigned to this group.
Study NCT01999179 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Heparin, Low-Molecular-Weight, or direct oral anticoagulants
Description: Cancer patients will be treated with enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing obtained by the clinical team or either apixaban, rivaroxaban, dabigatran, edoxaban following a catheter related blood clot
Study NCT03888859 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET1402L1-ARTEMIS™ T cells -IV
Description: Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct -intravenous (i.v.) arm
Study NCT03888859 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET1402L1-ARTEMIS™ T cells -intra-hepatic artery
Description: Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct: intra-hepatic artery (i.a.) arm
Study NCT03888859 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET1402L1-ARTEMIS™ T cells -Intratumoral Injections
Description: Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct: Intratumoral Injections (i.t.) arm
Study NCT05123898 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Soft tissue augmentation
Description: 1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Ostem dental implant (Osstem Implant Co., Ltd.)~3. Modeling of sterile collagen matrix according to the shape of the recipient bed~4. Fixation of the collagen matrix to the vestibular flap~5. Suturing the wound tightly
Study NCT05123898 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft tissue augmentation
Description: 1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Ostem dental implant (Osstem Implant Co., Ltd.)~3. Modeling of sterile collagen matrix according to the shape of the recipient bed~4. Fixation of the collagen matrix to the vestibular flap~5. Suturing the wound tightly
Study NCT02725086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neupogen®
Study NCT01199250 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02701413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ApexM (Stimulation) Device
Description: Vaginal electrical stimulation will be administered via the Apex M Device. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Stimulation session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
Study NCT00711217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Food
Description: twice daily
Study NCT02276521 — intervention group
Intervention type: BIOLOGICAL
Intervention: Cervarix®
Description: All groups will received one dose of Cervarix® vaccine
Study NCT00711217 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Drink mix calorically similar to experimental product
Description: twice daily
Study NCT00664404 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Functional Magnetic Resonance Imaging (fMRI)of the Brain, one session while smoking, and one session while abstinent from smoking (not smoking).
Study NCT04152317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 200mcg Tab
Description: In the misoprostol 200mcg group there will be one tablet of 200mcg and three identical tablets in shape, size and color without pharmacological properties. These four tablets will be single dose administered via vaginal route for each participant.
Study NCT04152317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 800mcg Tab
Description: In the misoprostol 800mcg group there will be four tablets of 200mcg. These four tablets will be single dose administered via vaginal route for each participant.
Study NCT02711059 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: parathyroidectomy
Description: surgical treatment of hyperparathyroidism
Study NCT00969137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: intravenous saline
Study NCT00969137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Intravenous nicotine
Study NCT04429685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Low dose ketamine - Ketalar (Racemic Ketamine Hydrochloride) Saline - Isotonic/Normal Saline
Study NCT04429685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (placebo)
Description: Saline (placebo)
Study NCT02526758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone
Study NCT02526758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: formoterol
Study NCT02526758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol
Study NCT02526758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Study NCT00467025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: 3 mg/kg or 10mg/kg IV weekly until unacceptable toxicity or disease progression
Study NCT03339258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin Mesylate, Extended Release
Description: Doxazosin is FDA-approved for the treatment of hypertension and urinary outflow problems associated with benign prostatic hyperplasia. The immediate-release formulation is approved for use from 1mg up to 16mg. Based on drug company information and Micromedex, the SFVA pharmacy on-line reference resource for drug information, the only contraindication to use of doxazosin is hypersensitivity to doxazosin, its contents, or other quinazolines (e.g. prazosin, terazosin).
Study NCT03339258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, or inactive pill.
Study NCT02793154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Supplied as SC injection containing 250 mcg/mL of exenatide, provided in the following dose regimens: Part A: 10 mcg taken twice daily for 5 days; Part B: 5 mcg twice daily taken for 4 weeks followed by uptitration to 10 mcg for 4 weeks In both parts, it will be administered within 60-minute period before morning and evening meals (or before 2 meals with approximate >=6 hours apart)
Study NCT02793154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Supplied as SC injection containing 250 mcg/mL of exenatide, provided in the following dose regimens: Part A: 10 mcg taken twice daily for 5 days; Part B: 5 mcg twice daily taken for 4 weeks followed by uptitration to 10 mcg for 4 weeks In both parts, it will be administered within 60-minute period before morning and evening meals (or before 2 meals with approximate >=6 hours apart)
Study NCT02701413 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: A sham Apex M device without electrical stimulation will be used. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Each session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
Study NCT00845234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Intervention consisted of a brief, educational CBT intervention and included the following domain areas: ICD knowledge and post-discharge care, understanding shock, stress management, family and relationships, device recall, and survivorship. The intervention was provided at baseline (0 weeks). Intervention was led by investigator and lasted 15 minutes in duration.
Study NCT00467025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg PO BID
Study NCT02793154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide
Description: Part B: Albiglutide will be supplied as follows:30 mg SC injection pen containing 40.3 mg lyophilized albiglutide and 0.65 mL; 50 mg SC injection pen contains 67 mg lyophilized albiglutide and 0.65 mL water; Starting dose will be 30 mg weekly for 4 weeks and then uptitrated to 50 mg weekly for 4 weeks; Administered as a single SC injection once a week in the morning
Study NCT04732338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Therapy
Description: Osteopathic Manipulative Therapy (OMT) is a non-pharmacological, noninvasive form of manual medicine. Osteopathic practitioners use a wide variety of therapeutic manual techniques to improve physiological function and help restore homeostasis in the body. There is a structural assessment is to identify possible abnormalities of tissue texture. Areas of asymmetry and misalignment of bony landmarks are also evaluated, along with the quality of motion, balance, and organization. These asymmetries, also known as somatic dysfunctions, are then treated by a variety of manual treatments, administered by osteopaths.
Study NCT00467025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 400 mg PO BID
Study NCT00467025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 placebo IV
Description: AMG 386 placebo IV
Study NCT00467025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 386 placebo IV
Description: AMG 386 placebo IV
Study NCT00003225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Description: Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. Administered every two weeks for 3 cycles.
Study NCT00003225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: 10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.~Administered every 14 days for 3 cycles
Study NCT01889654 — intervention group
Intervention type: OTHER
Intervention: Venous blood sampling
Study NCT01927419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT01927419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT01927419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching nivolumab
Study NCT01764256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P2-VP8 subunit rotavirus vaccine
Description: P2-VP8 subunit rotavirus vaccine was made by inserting a codon optimized synthetic gene for the VP8 region of rotavirus VP4 fused to the P2 T-cell epitope of tetanus toxin into the Pj411 proprietary cloning vector developed by DNA 2.0, Menlo Park, CA. The vector carries a kanamycin resistance gene as a selection marker. The vector was transfected into the BL21 strain of E. coli. The fusion protein was purified from Isopropyl β-D-1-thiogalactopyranoside (IPTG)-induced and physically lysed cultures using standard column chromatographic techniques employing Q-Sepharose and Butyl 650 as resins in addition to ultrafiltration and diafiltration.
Study NCT01764256 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Sodium Chloride 0.9%, USP for Injection was used to dilute the active P2-VP8 vaccine to final dosing concentration and was used for the Placebo for the study.
Study NCT00542724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIAject™
Description: Dosage as individually required
Study NCT00542724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular Human Insulin
Description: Dosage as individually required
Study NCT00664209 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: clartihromycin, amoxicillin, and omeprazole
Description: clarithromycin 500mg - i PO BID x10 days; amoxicillin 1gm - i PO BID x10 days; omeprazole 10mg - i PO BID x10 days
Study NCT00664209 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo therapy
Study NCT01613547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 80 mg/kg/day for 7 days
Study NCT03074396 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Use of DialysisNet for doctor
Description: DialysisNet is mobile application for physicians for haemodialysis patients. Patient-centred data integration and exchange were based on the American Society for Testing and Materials Continuity of Care Record standard.
Study NCT03074396 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Use of Avatar Beans for patient
Description: Avatar Beans is mobile application for haemodialysis patients. Patient-centred data integration and exchange were based on the American Society for Testing and Materials Continuity of Care Record.
Study NCT01791231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled 14C-canagliflozin (14C-JNJ-28431754)
Description: A single oral dose of 196 mg radiolabeled 14C-canagliflozin (14C-JNJ-28431754) liquid suspension containing approximately 40 microcurie (1480 kBq) of 14C radioactivity will be administered on Day 1.
Study NCT02377063 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Pressed Juice
Description: Subjects will be taking vegetable/fruit juice supplementation for 3 days. Blood, urine and stool samples will be collected at baseline, day 4 and day 17.
Study NCT02201290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag Tablets
Description: Eltrombopag tablets will be white, round film coated tablets containing eltrombopag olamine equivalent to 12.5 mg, 25 mg, 50 mg and 75 mg of eltrombopag. The 12.5 mg tablet will be smaller than the 25 mg, 50 mg and 75 mg tablets. Subjects will receive maximum dose of 75 mg once daily (QD).
Study NCT02201290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag PfOS
Description: Eltrombopag PfOS is a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet will contain eltrombopag olamine equivalent to 20 mg of eltrombopag per gram of powder. Subjects will receive maximum dose of 75 mg once daily (QD)
Study NCT02413931 — intervention group
Intervention type: OTHER
Intervention: Routine management practices applied
Description: all patients will be treated according to routine procedures, no intervention
Study NCT03237533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be applied locally on the lesion
Study NCT02672202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: * 60 mg/d - twice before surgery and once a day for post operative days 3-7~* 30 mg/d - once a day for post operative days 1-2
Study NCT02672202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: * 75 mg/d - twice a day for post operative days 1-2~* 150 mg/d - twice a day for post operative days 3-7 300 mg/d - twice before surgery
Study NCT02672202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: * non-active - twice before surgery~* non-active - twice a day for post operative days 1-7
Study NCT02672202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * non-active - twice before surgery~* non-active - twice a day for post operative days 1-7
Study NCT02025751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide Nasal Spray
Description: One 10 mg spray dose 30 minutes before meals and before bed for 28 days (QID)
Study NCT02025751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: One placebo spray dose 30 minutes before meals and before bed for 28 days (QID)